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Abstract
Vd2neg cd T cells, of which Vd1+ cd T cells are by far the largest subset, are important effectors against CMV infection.
Malignant gliomas often contain CMV genetic material and proteins, and evidence exists that CMV infection may be
associated with initiation and/or progression of glioblastoma multiforme (GBM). We sought to determine if Vd1+ cd T cells
were cytotoxic to GBM and the extent to which their cytotoxicity was CMV dependent. We examined the cytotoxic effect of
ex vivo expanded/activated Vd1+ cd T cells from healthy CMV seropositive and CMV seronegative donors on unmanipulated
and CMV-infected established GBM cell lines and cell lines developed from short- term culture of primary tumors. Expanded/
activated Vd1+ T cells killed CMV-negative U251, U87, and U373 GBM cell lines and two primary tumor explants regardless of
the serologic status of the donor. Experimental CMV infection did not increase Vd1+ T cell - mediated cytotoxicity and in
some cases the cell lines were more resistant to lysis when infected with CMV. Flow cytometry analysis of CMV-infected cell
lines revealed down-regulation of the NKG2D ligands ULBP-2, and ULBP-3 as well as MICA/B in CMV-infected cells. These
studies show that ex vivo expanded/activated Vd1+ cd T cells readily recognize and kill established GBM cell lines and
primary tumor-derived GBM cells regardless of whether CMV infection is present, however, CMV may enhance the resistance
GBM cell lines to innate recognition possibly contributing to the poor immunogenicity of GBM.
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Introduction
High-grade gliomas such as glioblastoma multiforme (GBM)
can initiate and progress to an unsalvageable point without
generating a significant immune response, consistent with
Medawar’s description of the brain as a site of relative immune
protection [1]. Human cytomegalovirus (HCMV) infection has
also been detected in a large percentage of human high-grade
gliomas, and recent studies suggest a relationship between HCMV
infection and initiation and/or progression of GBM [2–6]. The
presence of latent CMV infection in GBM could present an
opportunity for CMV-based immunotherapy, provided that such
an approach could overcome the highly immunosuppressive
microenvironment [7–11].
T cells bearing the c and d receptor (cd T cells) are important
effectors against malignancy-associated viral infections such as
EBV [12] and HSV [13]. Indeed, increases principally in
circulating Vd1+, and to a lesser extent Vd3+ and Vd5+ T cell
subsets [14], have been strongly and positively correlated with a
response to and subsequent resolution of HCMV viremia [15].
Most importantly, CMV-reactive Vd1+ cd T cells also are cross-
reactive against several malignant cell lines [15–18].
The Vd1 subset is normally ,10% of circulating cd T cells but
predominant in epithelial tissues. Vd1+ T cells are activated by
stress-induced self-antigens such as MIC-A/B and UL-16 binding
proteins through the T cell receptor and NKG2D [19–21] and
recognize glycolipids presented by CD1c on the surface of
immature dendritic cells and can induce DC to mature and
produce IL-12 [22,23]. This population comprises cells that are
highly cytotoxic to a wide variety of malignancies [24–29], and
long-term persistence of Vd1+ T cells in bone marrow transplant
patients has been associated with long-term disease free survival
[30,31]. Vd1-expressing T cells can also exhibit immunosuppres-
sive and regulatory properties in addition to effector function
[32,33], a finding of particular importance in determining the
interaction of cd T cells and malignancy. We have previously
shown that ex vivo expanded/activated cd T cells are highly
cytotoxic to glioma cell lines and primary GBM cell line explants,
and that these cd T cells will slow tumor progression and increase
survival in immunodeficient mice bearing GBM cell line xenograft
tumors [34,35]. Separately, we also showed that cd T cells are
globally reduced in GBM patients although the proportion of
circulating Vd1 T cells was increased [36]. In this report, we build
on previous work detailed above to determine if a Vd1+ T cell
response is evident in GBM patients, the potential for Vd1+ T cell-
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mediated immune reactivity against GBM, and the extent to
which CMV infection in high-grade gliomas affects their
immunogenicity to Vd1+ T cells.
Materials and Methods
Patients and healthy volunteers
Patients presenting with CT or MRI evidence of probable GBM
were accrued for this study and enrolled following histological
diagnosis. Patients and controls were excluded if they had been
diagnosed with a co-existing immune system disorder; active viral,
bacterial or parasitic infection; or prior organ or bone marrow
transplant. The University of Alabama at Birmingham (UAB)
Institutional Review Board for Human Research approved this
study. Written informed consent was obtained from each patient
or a designated family member. Written informed consent was
obtained from healthy volunteers following explanation of the
research studies.
Expansion of Peripheral Blood cd T cells and tumor-
infiltrating lymphocytes
Two methods were used to expand peripheral blood cd T cells
from healthy volunteers and GBM patients (n=5/group), one that
preferentially expands the Vc9Vd2 cell population (ZOL/IL-2)
and another that inhibits apoptosis in all cd T cell subsets (CD2/
OKT-3). In the ZOL/IL-2 method, mononuclear cells (MNC)
were obtained by density gradient centrifugation and resuspended
at 1.06106/ml in RPMI 1640+10% autologous serum +1 mM
Zoledronate (Novartis Oncology; East Hanover, NJ) +50 U/ml
IL-2 (Roche: Indianapolis, IN). The culture was maintained at the
original density for 14d with addition of 50 U/ml IL-2 on post-
culture days 2, 6, and 10 and addition of complete media as
determined by pH and cell density. In the CD2/OKT-3 method
described by Lopez [37], cultures were initiated in RPMI-1640
supplemented with L-glutamine, and 10% human serum 10%
1 M HEPES, 1,000 U/ml human rIFN-c, 10 U/ml human rIL-
12, and 1 mg/ml mouse anti-human CD2 mAb clone CLB-CD2
6G4 (Baxter Oncology, Deerfield, IL). Twenty-four hours later,
10 ng/ml anti-CD3 mAb OKT3 (Ortho Biotech) and 300 U/ml
recombinant-human (rHu) IL-2 were added to the culture media
and maintained at the original density for 14 d with addition of
complete media as determined by pH and cell density. Tumor-
infiltrating lymphocytes cultures were initiated from fresh GBM
tumors from operative specimens. Tissues were minced finely with
#11 scalpel blades followed trypsin and collagenase type IV for
2 h at room temperature. After digestion, the cells were washed
twice in RPMI1640 and cultured using only the CD2/OKT-3
method as described above and maintained for 14 d with the
addition of fresh complete media as needed.
Expansion and activation of Vd1+ cd T cells from healthy
volunteers
Up to 50 ml of peripheral blood was obtained from healthy
volunteers. Peripheral blood mononuclear cells (PBMC) were
isolated by density gradient centrifugation and resuspended at a
concentration of 16106 cells/ml in RPMI-1640 supplemented
with 10% pooled human serum. Vd1+ T cells were sorted from
PBMC using anti-Vd1 (R9.12 Beckman Coulter) and ferromag-
netic particles (Miltenyi Biotech; Bergen Gladbach, Germany).
Purified Vd1 T cells were expanded in 200 IU/ml recombinant
IL-2 (R&D Systems; Abingdon, UK), 1 mg/ml PHA-L (Sigma-
Aldrich; Taufkirchen, GE) and irradiated allogeneic PBMC feeder
cells. After 3 weeks of culture, the resulting effector lines were
phenotyped and purity (routinely .95%) was determined by
multicolor fluorescent staining.
Cell Lines
U251, U87, and U373 are established GBM cell lines that were
obtained from the Brain Tumor Tissue Facility at UAB and have
been verified to be authentic by short-tandem repeat PCR
conducted by the UAB Cancer Genomics Core Facility (Michael
Crowley, Director). The U87 is a grade IV glioma that originated
from a 44-year-old Caucasian woman [38]. The genetic charac-
teristics of the cell line have been well described [39]. The UAB
Brain Tumor Tissue Core, a unit of the UAB NCI SPORE in
Brain Cancer, obtained the cell line from the ATCC. Its origin has
been verified by STR PCR and has been found to agree with the
original cell source. U251MG is a grade III astrocytoma that was
cultured from a 61 year old male [38] and was obtained directly
from Darell D. Bigner (Duke University) who obtained them from
Jan Ponten of Uppsala University. The cell line has been verified
as authentic (Rb-deleted, p15/p16 wild type) and has the same
STR pattern as the original line. U373MG has been previously
identified as a subclone of the U251 cell line [40]. Cell lines were
cultured in a 50:50 mixture of Dulbecco’s Minimum Eagle’s
Medium and Ham’s Nutrient Mixture F-12 (DMEM/F12 50:50)
enriched with 7% heat inactivated pooled human cGMP-grade
serum (Labquip; Woodbridge, ON), 2 mM L-glutamine and 10%
Penicillin-Streptomycin-Amphotericin (Mediatech; Herndon VA).
The human fetal lung fibroblast line MRC5 was obtained from
European Collection of Cell Cultures (ECACC). Cells were
cultured in MEM supplemented with 2 mM L-glutamine,
nonessential amino acids (all from Sigma Aldrich) and 10%
FCS. Fibroblasts were used between 32–40 passages and were
maintained at 37uC in a humid atmosphere containing 5% CO2.
Primary Tumor Explant Cultures
Short-passage primary GBM cultures were initiated from
intraoperative specimens obtained from accrued patients. Tissue
for explant was transferred aseptically into T75 flasks in about
15 ml of ‘‘complete culture medium’’ which is DMEM/F12 50:50
(Mediatech; Herndon VA) supplemented to 7% with heat-
inactivated fetal bovine serum and 2.6 mM L-glutamine. The
medium was exchanged after 5–7 days and any cells growing out
from the explants were maintained in primary culture. The
cultures were monitored for growth and confluence and the media
was changed weekly. Once cells on the flask were confluent, the
cells were detached using trypsin and passaged and/or cryopre-
served.
Immunohistochemistry
Paraffin embedded sections of primary GBM were used for
immunohistochemistry. Antibodies and sources were as follows:
HCMV IE-1 (Millipore: Billerica, MA), MIC A/B (Bio Legend;
San Diego, CA), ULBP-1, ULBP-2, ULBP-3, and ULBP-4 (Santa
Cruz Biotechnology; Santa Cruz, CA). Sections of normal brain
served as the antibody control and sections not labeled with
primary antibody served as control for background. Specimens
were deparaffinized in xylene and rehydrated by ethanol washes at
decreasing concentrations (100%, 95%, 70%) followed by PBS.
Boiling the sections for 5 min with EDTA in the pressure cooker
was performed for antigen retrieval. Endogenous peroxidase
quenching was performed with 3% peroxide for 5 min and rinsed
with Tris buffer. 3% normal goat serum was then applied as a
blocking agent for 20 min. Primary antibody was applied for one
hour. Goat anti-mouse/anti-rabbit secondary antibody (Biogenex,
San Ramon CA) was applied for 20 minutes followed by HRP for
Vd1+ cd T Cell Response to Glioblastoma
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20 min. Diaminobenzidine tetrahydrochloride (DAB) (Biogenex,
San Ramon CA) was then applied for ,8 min. After DAB
staining, slides were rinsed with DI water and counterstained with
pure hematoxylin for 45 s. Then the slides were dehydrated with
graded ethanol and xylene and mounted in coverslips.
In situ hybridization
For detection of HCMV nucleic acids, a biotinylated 21-base
oligonucleotide (59-GTGGTGGCGCTGGGGGTGGCG-39)
specific for HCMV early gene mRNA and biotinylated positive
(specific for polyadenylic mRNA) and negative control (specific for
HSV-1/2) probes were obtained (Novocastra; Buffalo Grove, IL).
We performed enzyme digestion and nucleic acid denaturation of
paraffin sections using a Misha thermocycler (Shandon Lipshaw,
Pittsburgh, PA), and slides were hybridized overnight at 37uC in a
humidified chamber (methods are detailed in manuscript in
preparation). 4 Probe was detected using a supersensitive detection
system (BioGenex, chromogen NBT). To detect HCMV DNA, we
used a digoxigenin-labeled HCMV total genome DNA probe
(Zymed Labs, South San Francisco, CA). The manufacturer
provided positive (specific for endogenous alu DNA sequence) and
negative (nonspecific DNA) digoxigenin-labeled control probes.
CMV strains, infection procedure
Both clinical CMV strains TB40/E and VHL/E were kindly
provided by Dr. Christian Sinzger (University of Tubingen,
Germany). For infection, 56105 MRC5 fibroblasts per well were
seeded into 24-well plate 24 h before adding the virus. Sub-
confluent monolayers of MRC5 fibroblasts were incubated with
CMV in suspension at multiplicity of infection (MOI) of 1–5 for
2 h at 37uC. After virus adsorption, cells were washed and
cultured for 2–4 days. Infection was verified by microscopy to
determine the cytopathic effect.
Cytotoxicity assays
Targets are labeled with the membrane dye PKH26 (Sigma; St.
Louis, MO). Expanded/activated cd T cells are then added to the
tubes at ratios of 0:1 (Background), 5:1, 10:1, 20:1 and 40:1
effectors/GBM targets, incubated for four hours at 37uC and 5%
CO2, washed61 and resuspended in 1 ml HBSS. To-Pro Iodide
solution (Molecular Probes; Eugene, OR) 20 ml is added prior to
acquisition on the flow cytometer. Cytotoxicity is calculated by
dividing the number of PKH26+ToPro Iodide+ events by the total
number pf PKH16+ events and multiplying the result by 100.
Statistical methods
Descriptive statistics and nonparametric analysis using the
Wilcoxon log-rank test was used to test for differences in expansion
of cd T cells observed between healthy donors and GBM patients
and differences cytotoxicity of Vd1+ T cells between CMV+ and
CMV2 donors. Where applicable, paired-ttests were used to
compare cytotoxicity data and NKG2DL expression (data
normally distributed).
Figure 1. Flow cytometry dot plots cd T cell expansion cultures of peripheral blood from five pre-resection GBM patients and one
healthy volunteer. The cd T cells were expanded/activated by either (a) CD2/OKT-3 or (b) ZOL/IL-2 methods as described in the text. Peripheral
blood from a representative healthy control is shown at right. After 14 days in culture, neither method was effective in expanding cd T cells from the
blood of any of the five GBM patients although cd T cells from healthy volunteers were readily induced to proliferate (p = 0.12 for both methods).
doi:10.1371/journal.pone.0068729.g001
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Results
Peripheral blood cd T cells obtained from patients prior
to treatment and GBM-infiltrating cd T cells obtained
from resected tumor show minimal response to ex vivo
stimulation
We previously reported that the proportion of circulating Vd1+
T cells is increased in GBM patients and that the absolute Vd1+ T
cell count did not significantly differ from older healthy volunteers
[36]. In these experiments, we cultured peripheral blood
mononuclear cells (MNC) from five GBM patients in an effort
to determine whether the Vd1+ T cells could respond to ex vivo
stimuli and whether sufficient numbers of cells could be obtained
for cloning and assay for anti-CMV activity. As shown in Figure 1,
cd T cells from patients with GBM failed to expand using either
the ZOL/IL-2 or CD2/OKT-3 culture conditions. Less than 5-
fold expansion was seen in all peripheral blood specimens from
GBM patients by both methods, neither of which showed a
significant advantage in expanding cd T cells from GBM patients
(p = 0.12). In contrast, cd T cells from healthy volunteers
expanded well using CD2/OKT-3 (n= 7, median = 200 with
range 100 to 375 fold) or ZOL/IL-2 (n = 5, median= 223 fold,
range 46 to 435 fold). Few cd T cells were seen in tumor
infiltrating lymphocytes (TIL) preparations obtained from freshly
resected GBM tumors and these also did not respond to T cell
stimulation culture. (Figure 2).
Cultured Vd1+ T cells from CMV-seronegative and CMV-
seropositive healthy volunteers lyse standardized glioma
cell lines and short-passage primary explants from GBM
tumors equally well
Vd1+ T cells from CMV- (Donor 1) and CMV+ (Donor 2)
healthy volunteers cultured using a standardized culture method
developed in our laboratory [18] consistently yielded over 90%
Vd1+ T cells (Figure 3a) and efficiently lysed glioma cell lines
U87, U251 and U373 and primary GBM explants designated
1016 and 1042 (Figure 3b and Figure s1). Expanded/activated
Vd1+ T cells were not cytotoxic to cultured human astrocytes in
E:T ratios up to 20:1. Cytotoxicity against CMV-infected
astrocytes was ,5% at the highest E:T ratio (20:1) assessed.
Additional experiments that incorporated cytolytic activity of
Vd1+ T cell cultures from CMV seropositive (n = 4) and CMV
seronegative (n = 6) donors against U251 cells and the GBM
primary explant line 1042 (Figure 3c) revealed no significant
impact on cytotoxicity based on CMV serologic status (p = 0.75
and p= 0.29 respectively).
After establishing that Vd1+ T cells are cytotoxic to GBM cells,
we next considered whether this Vd1+ T cell-mediated recognition
and lysis of primary glioma explants could be associated with
latent CMV infection. Indeed, the two primary GBM tumors from
which cell explants 1016 and 1042 were derived expressed CMV-
associated antigens IE-1 and pp65 (Figure 4a) as well as CMV
mRNA (Figure 4b, upper panel). CMV mRNA was also
Figure 2. Culture of tumor infiltrating lymphocytes (TIL) from a representative human GBM. Note an initial very low percentage of cd T
cells that could not be expanded in two week culture using the CD2/OKT3 method (see text). Flow cytometric dot plots were gated on CD3+
lymphocytes. Similar results were obtained from three additional patients.
doi:10.1371/journal.pone.0068729.g002
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detectable in both cell lines (Figure 4b) suggesting continued
CMV infection. As expected and previously reported, there was no
evidence of deep parenchymal T cell invasion of these tumors
(Figure 4a). Strong expression of Vd1+ T cell target NKG2D
ligands (NKG2DL) ULBP-2 and ULBP-3 and moderate expres-
sion of ULBP-1 was noted on both tumor cell lines. There was
little to no expression of MIC-A/B on either line (Figure 5).
Experimental acute CMV infection of selected glioma cell
lines is associated with a reduction of NKG2DL
expression and in some cases reduced cytotoxicity
In order to determine the impact of CMV infection on tumor
vulnerability to Vd1+ T cells, we infected the CMV-negative
glioma cell line U251 with CMV strain TB40/E and assessed
Vd1+ T cell cytotoxicity against both the infected and unmanip-
ulated cell lines. Expanded/activated Vd1+ T cells lysed both
CMV-infected and unmanipulated U251 cells, although a
significant reduction in cytotoxicity to CMV-infected U251 cells
was noted at the E:T ratio of 20:1 (n = 6, p = 0.021). Figure 6a
shows results of cytotoxicity assays against U251 from three
representative donors. When examined separately, donor CMV
serologic status (n = 3 seropositive and 3 seronegative) was not a
factor in lysis of either infected or unmanipulated cells (p = 1.00 at
1:20 effector:target ratio, data not shown). Figure 6b compares
NKG2DL expression between unmanipulated U251 cells and
U251 cells that had been infected in culture for 5 days. MIC A/B
and ULBP-2 were consistently down regulated in CMV-infected
U251 cell cultures. ULBP-1 and ULBP-3 expression was variable
between cultures. When CMV-infected U251 cells were assessed
based on expression of HCMV-IE-1 expression (Figure 6c),
however, it was noted that cells strongly expressing IE-1 (red
histograms) generally showed little change in MIC-A/B expression
when compared to a parallel unmanipulated culture (black
histograms). Unmanipulated cells do not express IE-1 (data not
shown) and expressed all UL-16 binding proteins at higher density
than CMV-infected cells. Interestingly, the IE-1neg population
(blue) showed only ULBP-2 expression. This population contains a
mixture of fragile infected and non-viable cells many of which
have shed these surface markers. Taken together, as Vd1+ T cells
Figure 3. Cytotoxicity of expanded/activated Vd1+ T cells from CMV seropositive and seronegative healthy volunteers against
human glioma cell lines. (a) Flow cytometric analysis of 14-day expansion culture of purified Vd1+ T cells from two healthy volunteer donors. (b)
Cytotoxicity of purified and expanded Vd1+ T cells from two donors against three (left to right for each donor) GBM cell lines (a) U251, (b) U87, and (c)
U373 and two primary cell lines from GBM explants designated (d)1016 and (e)1042 in a four-hour cytotoxicity assay at an E:T ratio of 20:1. (c) Vd1+ T
cell cultures were expanded from additional CMV-seropositive (n = 4) and CMV-seronegative (n = 6) donors as described in the text and reacted over
4 h at an E:T ratio of 20:1 is shown with the U251MG glioma cell line and the 1024 primary GBM explant line. Donor CMV serologic status had no
effect on Vd1+ T cell cytotoxicity against U251 (p = 0.75) or 1042 (p = 0.29), respectively for CMV seropositive and CMV seronegative donors.
doi:10.1371/journal.pone.0068729.g003
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are known to recognize NKG2D ligands as a mechanism for
cytotoxic activity, these findings suggest that the extent to which
different glioma cell lines regulate NKG2DL expression in
response to CMV infection is variable and may be associated
with partial protection from Vd1+ T cell – mediated lysis.
Discussion
In previous work we have shown that cd T cell cultures cultured
ex vivo using a combination of anti-CD2, OKT-3, and IL-2 are
cytotoxic to high-grade gliomas in vitro and to human xenograft
tumors in immunodeficient mice [34,35]. We now extend our
previous findings to examine the specific function of the Vd1+ T
cell population in the context of the immune response and
potential immunotherapies for malignant glioma. Clinical data
and murine models both support a vigorous cd T cell response to
CMV infection [14,41] that is skewed toward Vd2- in humans.
This Vd2- population is comprised principally of Vd1+ T cells, a
population with both cytotoxic and regulatory/suppressive roles in
malignancy and infection [33]. Understanding of the function of
Vd1+ T cells in the immune response to cancer is currently
limited, particularly with respect to glioblastoma tumors that have
shown persistent CMV infection.
Strategies for expansion of circulating Vc9Vd2+ T cells have
been elusive. Indeed, our laboratory and others have extensively
reported poor persistence, death, and functional anergy of ex vivo
expanded/activated Vc9Vd2+ T cells, particularly when they are
obtained from cancer patients [35,42–44]. Ex vivo expansion of
Vd1+ cd T cells, however, has met with some success, particularly
when cells are obtained from patients with neuroblastoma and
myeloma [26,45,46]. Vd1+ cd T cells GBM patients, however,
were resistant to ex vivo stimulation methods that readily expand
this population in healthy volunteers and appear to be functionally
anergic.
We then tested the cytotoxicity of ex vivo expanded Vd1+ T cells
from healthy volunteers against standardized glioma cell lines and
two cultured explants derived from primary brain tumors grown in
short-term culture to determine if CMV infection was associated
with vulnerability to recognition and lysis. The two primary tumor
explants designated 1042 and 1016 were effectively lysed by ex vivo
expanded Vd1+ T cells (Figure 3 and Figure s1) and were
shown to be positive for CMV infection both in sections from the
primary tumors and the short-passage cell lines derived from them.
We were able to demonstrate strong expression of pp65 and IE-1
as well as the presence of CMV mRNA in the primary GBM
tumors from which the cell preparations were obtained. Cultured
cells from these tumors also showed evidence of continued CMV
infection (Figure 4) and expressed several stress-associated
NKG2D ligands (Figure 5). However, Vd1+ T cells also
consistently lysed U251MG, U87MG, and U373 GBM cell lines,
which do not express CMV-associated antigens nor do they
harbor replicating CMV. These findings are consistent with earlier
work from this laboratory that documents significant CMV-
independent cytotoxicity of purified Vd1 T cells against leukemia
and myeloma cell lines and primary leukemia [30,31,46].
Cytotoxicity of cd T cells against tumor cells and virus-infected
cell lines is broadly based and is generally related to expression of
stress-associated surface proteins [19,47]. We have previously
shown that cd T cells with strong cytotoxicity to glioma cell lines
do not kill normal human astrocytes in culture [48], and in this
work we have also shown that CMV-infected astrocytes are also
not killed by cytotoxic Vd1+ T cells. Separately, we have also
shown essentially negative cytotoxicity toward uninfected vs.
strong cytotoxicity toward CMV-infected MRC fibroblasts [18].
Taken together, these data strongly suggest that Vd1+ T cell
Figure 4. Assessment of CMV activity in primary GBM and derived cell lines. (a) Primary GBM from which cell explants 1016 and 1042 were
derived expressed CMV-associated surface antigens IE-1 and pp65, although T cell invasion beyond perivascular areas as indicated by anti-CD3
labeling is minimal. (b) Both primary tumors 1016 and 1042 (top panel) were assessed for the presence of CMV mRNA by in-situ hybridization using a
biotinylated 21-base oligonucleotide (59-GTGGTGGCGCTGGGGGTGGCG-39) specific for HCMV early gene mRNA and a biotinylated positive (specific
for polyadenylic mRNA) and negative control (specific for HSV-1/2) probe. provided positive (specific for endogenous alu DNA sequence) and
negative (nonspecific DNA) digoxigenin-labeled control probes. Both tumors show the presence of CMV mRNA as do the short passage cell lines that
were derived from them (bottom panel) suggesting continued CMV infection.
doi:10.1371/journal.pone.0068729.g004
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recognition and cytotoxicity against gliomas is at least in part
modulated by expression of stress-induced NKG2DL and
independent of latent or persistent CMV infection.
Although our findings suggest that Vd1+ T cells were not
dependent on CMV infection in order to recognize and lyse
gliomas, Vd1+ T cells potentially could recognize glioma cells
based on previous exposure to CMV. This ‘‘crossover’’ cytotox-
icity was first shown by Halary [16], who found that that Vd2neg T
cells (of which Vd1+ T cells are the predominant population) both
recognize and respond to CMV-infected fibroblasts and lyse the
HT-29 intestinal tumor cell line independent of CMV infection.
Based on this previous work, we examined the cytotoxic function
of expanded Vd1+ T cells obtained from healthy CMV
seropositive and seronegative donors against standardized glioma
cell lines and against cells cultured from freshly resected GBM. We
were unable to demonstrate any difference in cytotoxicity between
Vd1+ T cells expanded from either CMV+ or CMV2 donors
against the glioma targets (Figure 3). These findings are
consistent with earlier work that found that although an expanded
and clonally restricted Vd1+ T cell population could be
documented both in CMV-seropositive and CMV- seronegative
healthy individuals, the cytolytic response to CMV-infected
fibroblasts was no different between the donor groups [18].
Having established that Vd1+ T cell-mediated recognition and
lysis was not dependent on CMV infection, we then asked whether
CMV infection could potentiate or inhibit Vd1+ T cell recognition
of gliomas. When standardized CMV- glioma cell lines were
artificially infected with CMV, Vd1+ T cell cytotoxicity against
glioma cell line targets was either less or the same at comparable
effector:target ratios (Figure 6). CMV infection did not result in
increased vulnerability of GBM cell lines to Vd1+ T cell mediated
cytotoxicity. Inhibition of Vd1+ T cell cytotoxicity to CMV-
infected GBM could occur through several mechanisms. Para-
doxically, down-regulation of NKG2D has been shown in NK
cells when exposed to CMV infected glioma, a response thought to
be associated with control of the immune response to virus CMV
Figure 5. Assessment of stress antigen expression cell lines derived from primary GBM. Primary GBM cell line explants 1016 and 1042
were labeled with fluorochrome-tagged antibodies to respective isotype control anti-IgG (clear) and Vd1+ T cell target NKG2DL MIC A/B, ULBP-1,
ULBP-2 and ULBP-3 (shaded). Strong expression of ULBP-2 and ULBP-3 is noted. Primary 1042 is a heterogeneous tumor with a brightly
autofluorescent subpopulation seen as a bimodal peak for both isotype and labeled plots.
doi:10.1371/journal.pone.0068729.g005
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infection [49], as has the sequestration of NKG2DL on infected
cells [50]. Blocking of MIC-A/B and individual UL-16 binding
proteins decreases cytotoxicity of cd T cells to U251MG cells but
do not abrogate cytotoxicity entirely [48]. Blocking of 4 NKG2DL
simultaneously decreases cytotoxicity by approximately 40%,
consistent with the reduced cytotoxicity seen in CMV-infected
U251MG. Indeed, our findings detailed in Figure 6b shows
modulation of MIC-A/B and ULBP-2 consistent with previous
reports of UL-16 sequestration or modulation of expression in
multiple NKG2D ligands in CMV-infected cells. [51,52]. Taken
together, these findings suggest that sequestration of NKG2DL
MIC-A and ULBP-2 in CMV-infected U251MG cells is a
contributing factor to decreased immunogenicity of glioma cells
to recognition by NK and cd T cells. These findings, however,
must be interpreted in the context of experimental CMV infection,
which is substantially different than the long-term latent CMV
infection of GBM in situ. A further complication is the use of CMV
strains that are propagated in the laboratory that may have critical
differences from the CMV strains that have been isolated from
GBM. Investigators have recently published an in vitro model of
long-term CMV infection in a GBM cell line that can retain the
virus in multiple passages which if reproducible and successful in
animal models may reflect CMV interaction with GBM and the
immune microenvironment with greater accuracy [53]
In summary, we have shown that pure cultures of expanded and
activated allogeneic Vd1+ cd T cells are cytotoxic to primary
glioma and glioma cell lines. Experimental CMV infection does
not render the glioma cell lines more vulnerable to lysis by cd T
cells and in some cases will decrease immunogenicity by down-
regulation of NKG2D ligands expression. In addition, cd T cells
from CMV-seropositive individuals do not show enhanced cross-
reactivity to primary tumor explants or glioma cell lines as has
been seen in other tumor types. These findings suggest that Vd1+
cd T cells are potent effectors against glioma, are not dependent of
CMV infection for their cytotoxicity, and should be further
explored in the design of immunotherapeutic strategies for high-
grade brain tumors.
Supporting Information
Figure S1 Detail of Cytotoxicity of Vd1+ T cells against
glioma cell lines and primary GBM at a range of
Effector:Target ratios from Figure 3b.
(TIF)
Figure 6. CMV infection modulated NKG2DL expression on glioma cell lines and their vulnerability to lysis by Vd1+ T cells. (a) Lysis of
unmanipulated U251MG cells (filled circles) versus CMV-infected U251MG cells (open circles) by expanded/activated Vd1+ T cells for three
representative donors in a 4 h flow cytometric cytotoxicity assay. CMV-infected cells are more resistant to lysis (p = 0.021) at E:T ratio of 20:1. (b)
Expression of NKG2DL on three cultures of unmanipulated (CMV-) vs. CMV-infected (CMV+) U251 glioma cultures as determined by Median
Fluorescence Intensity (MFI) following acquisition of a minimum of 10,000 events. (c) Expression of NKG2DL on unmanipulated (black), HCMV IE-1
expressing (red) and IE-1neg (blue) U251 glioma cells after 5 days of culture (see text).
doi:10.1371/journal.pone.0068729.g006
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